The Liposarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Liposarcoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Liposarcoma . Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Liposarcoma and features dormant and discontinued products.
GlobalData tracks 88 drugs in development for Liposarcoma by 69 companies/universities/institutes. The top development phase for Liposarcoma is phase ii with 53 drugs in that stage. The Liposarcoma pipeline has 84 drugs in development by companies and four by universities/ institutes. Some of the companies in the Liposarcoma pipeline products market are: AstraZeneca, Pfizer and Chia Tai Tianqing Pharmaceutical Group.
The key targets in the Liposarcoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22), and Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22).
The key mechanisms of action in the Liposarcoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with 12 drugs in Phase II. The Liposarcoma pipeline products include 16 routes of administration with the top ROA being Intravenous and ten key molecule types in the Liposarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Liposarcoma overview
Liposarcoma is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as a cancer (malignant) because of its potential to recur locally and spread to other areas of the body. The severity of disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumor. The specific genetic cause of liposarcoma has yet to be identified, though studies have proposed that it starts in fat cells that have lost their ability to mature or have unregulated growth
For a complete picture of Liposarcoma ‘s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
